nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.635	1	CbGbCtD
Dabrafenib—Nephritis—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0624	CcSEcCtD
Dabrafenib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00719	0.0417	CcSEcCtD
Dabrafenib—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00664	0.0385	CcSEcCtD
Dabrafenib—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00648	0.0376	CcSEcCtD
Dabrafenib—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00605	0.0351	CcSEcCtD
Dabrafenib—Cyst—Riluzole—amyotrophic lateral sclerosis	0.0055	0.0319	CcSEcCtD
Dabrafenib—NEK11—medulla oblongata—amyotrophic lateral sclerosis	0.00531	0.101	CbGeAlD
Dabrafenib—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00529	0.0307	CcSEcCtD
Dabrafenib—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00447	0.0259	CcSEcCtD
Dabrafenib—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00407	0.0236	CcSEcCtD
Dabrafenib—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00405	0.0235	CcSEcCtD
Dabrafenib—RAF1—hindbrain—amyotrophic lateral sclerosis	0.00391	0.0741	CbGeAlD
Dabrafenib—NEK11—cerebellum—amyotrophic lateral sclerosis	0.00375	0.0711	CbGeAlD
Dabrafenib—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00368	0.0213	CcSEcCtD
Dabrafenib—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00333	0.0193	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00307	0.0178	CcSEcCtD
Dabrafenib—NEK11—brain—amyotrophic lateral sclerosis	0.00305	0.0577	CbGeAlD
Dabrafenib—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00294	0.0171	CcSEcCtD
Dabrafenib—LIMK1—cerebellum—amyotrophic lateral sclerosis	0.00268	0.0509	CbGeAlD
Dabrafenib—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00268	0.0155	CcSEcCtD
Dabrafenib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00248	0.0144	CcSEcCtD
Dabrafenib—RAF1—embryo—amyotrophic lateral sclerosis	0.00245	0.0463	CbGeAlD
Dabrafenib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00243	0.0141	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0024	0.0139	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00236	0.0137	CcSEcCtD
Dabrafenib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00226	0.0131	CcSEcCtD
Dabrafenib—RAF1—brainstem—amyotrophic lateral sclerosis	0.00224	0.0425	CbGeAlD
Dabrafenib—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00221	0.0128	CcSEcCtD
Dabrafenib—LIMK1—brain—amyotrophic lateral sclerosis	0.00218	0.0413	CbGeAlD
Dabrafenib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00216	0.0125	CcSEcCtD
Dabrafenib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0119	CcSEcCtD
Dabrafenib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0119	CcSEcCtD
Dabrafenib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00201	0.0116	CcSEcCtD
Dabrafenib—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.002	0.0116	CcSEcCtD
Dabrafenib—SIK1—medulla oblongata—amyotrophic lateral sclerosis	0.00196	0.0372	CbGeAlD
Dabrafenib—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00196	0.0114	CcSEcCtD
Dabrafenib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00194	0.0113	CcSEcCtD
Dabrafenib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00186	0.0108	CcSEcCtD
Dabrafenib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0107	CcSEcCtD
Dabrafenib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00182	0.0106	CcSEcCtD
Dabrafenib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00182	0.0106	CcSEcCtD
Dabrafenib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00182	0.0105	CcSEcCtD
Dabrafenib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00181	0.0105	CcSEcCtD
Dabrafenib—SIK1—spinal cord—amyotrophic lateral sclerosis	0.00175	0.0332	CbGeAlD
Dabrafenib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00173	0.01	CcSEcCtD
Dabrafenib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00972	CcSEcCtD
Dabrafenib—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00968	CcSEcCtD
Dabrafenib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00965	CcSEcCtD
Dabrafenib—BRAF—cerebellum—amyotrophic lateral sclerosis	0.00166	0.0314	CbGeAlD
Dabrafenib—Chills—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00961	CcSEcCtD
Dabrafenib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00957	CcSEcCtD
Dabrafenib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00947	CcSEcCtD
Dabrafenib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00939	CcSEcCtD
Dabrafenib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00933	CcSEcCtD
Dabrafenib—RAF1—medulla oblongata—amyotrophic lateral sclerosis	0.00156	0.0296	CbGeAlD
Dabrafenib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00902	CcSEcCtD
Dabrafenib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00897	CcSEcCtD
Dabrafenib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00862	CcSEcCtD
Dabrafenib—SIK1—nervous system—amyotrophic lateral sclerosis	0.00148	0.028	CbGeAlD
Dabrafenib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00835	CcSEcCtD
Dabrafenib—SIK1—central nervous system—amyotrophic lateral sclerosis	0.00142	0.0269	CbGeAlD
Dabrafenib—Cough—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00814	CcSEcCtD
Dabrafenib—RAF1—spinal cord—amyotrophic lateral sclerosis	0.00139	0.0264	CbGeAlD
Dabrafenib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00805	CcSEcCtD
Dabrafenib—SIK1—cerebellum—amyotrophic lateral sclerosis	0.00139	0.0263	CbGeAlD
Dabrafenib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00794	CcSEcCtD
Dabrafenib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00794	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00788	CcSEcCtD
Dabrafenib—BRAF—brain—amyotrophic lateral sclerosis	0.00135	0.0255	CbGeAlD
Dabrafenib—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00776	CcSEcCtD
Dabrafenib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00761	CcSEcCtD
Dabrafenib—Infection—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00756	CcSEcCtD
Dabrafenib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00746	CcSEcCtD
Dabrafenib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00745	CcSEcCtD
Dabrafenib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00739	CcSEcCtD
Dabrafenib—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00736	CcSEcCtD
Dabrafenib—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00711	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00693	CcSEcCtD
Dabrafenib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00688	CcSEcCtD
Dabrafenib—RAF1—nervous system—amyotrophic lateral sclerosis	0.00117	0.0223	CbGeAlD
Dabrafenib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00662	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00657	CcSEcCtD
Dabrafenib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00656	CcSEcCtD
Dabrafenib—RAF1—central nervous system—amyotrophic lateral sclerosis	0.00113	0.0214	CbGeAlD
Dabrafenib—SIK1—brain—amyotrophic lateral sclerosis	0.00113	0.0214	CbGeAlD
Dabrafenib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00651	CcSEcCtD
Dabrafenib—RAF1—cerebellum—amyotrophic lateral sclerosis	0.00111	0.0209	CbGeAlD
Dabrafenib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00622	CcSEcCtD
Dabrafenib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00602	CcSEcCtD
Dabrafenib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00602	CcSEcCtD
Dabrafenib—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000967	0.00561	CcSEcCtD
Dabrafenib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000942	0.00546	CcSEcCtD
Dabrafenib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000929	0.00538	CcSEcCtD
Dabrafenib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000898	0.00521	CcSEcCtD
Dabrafenib—RAF1—brain—amyotrophic lateral sclerosis	0.000898	0.017	CbGeAlD
Dabrafenib—SLC22A6—brain—amyotrophic lateral sclerosis	0.000872	0.0165	CbGeAlD
Dabrafenib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000868	0.00503	CcSEcCtD
Dabrafenib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000834	0.00484	CcSEcCtD
Dabrafenib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000828	0.0048	CcSEcCtD
Dabrafenib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000827	0.00479	CcSEcCtD
Dabrafenib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000822	0.00477	CcSEcCtD
Dabrafenib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00078	0.00452	CcSEcCtD
Dabrafenib—SLC22A8—nervous system—amyotrophic lateral sclerosis	0.000683	0.0129	CbGeAlD
Dabrafenib—SLC22A8—central nervous system—amyotrophic lateral sclerosis	0.000657	0.0125	CbGeAlD
Dabrafenib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000647	0.0123	CbGeAlD
Dabrafenib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000576	0.0109	CbGeAlD
Dabrafenib—SLC22A8—brain—amyotrophic lateral sclerosis	0.000522	0.00989	CbGeAlD
Dabrafenib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000499	0.00945	CbGeAlD
Dabrafenib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000457	0.00866	CbGeAlD
Dabrafenib—CYP2C8—brain—amyotrophic lateral sclerosis	0.000382	0.00724	CbGeAlD
Dabrafenib—ABCG2—brain—amyotrophic lateral sclerosis	0.000371	0.00704	CbGeAlD
Dabrafenib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000338	0.00641	CbGeAlD
Dabrafenib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000326	0.00617	CbGeAlD
Dabrafenib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000319	0.00604	CbGeAlD
Dabrafenib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000284	0.00539	CbGeAlD
Dabrafenib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.00024	0.00454	CbGeAlD
Dabrafenib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000231	0.00437	CbGeAlD
Dabrafenib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000225	0.00427	CbGeAlD
Dabrafenib—ABCB1—brain—amyotrophic lateral sclerosis	0.000183	0.00347	CbGeAlD
Dabrafenib—LIMK1—Axon guidance—MMP9—amyotrophic lateral sclerosis	0.000135	0.000961	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—DAO—amyotrophic lateral sclerosis	0.000132	0.000943	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000131	0.000937	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ATF1—amyotrophic lateral sclerosis	0.00013	0.000931	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.00013	0.00093	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.000129	0.000923	CbGpPWpGaD
Dabrafenib—CYP2C8—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000128	0.000915	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000128	0.000914	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000128	0.000913	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000128	0.000912	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000128	0.000912	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000127	0.000904	CbGpPWpGaD
Dabrafenib—RAF1—Disease—VTA1—amyotrophic lateral sclerosis	0.000124	0.000888	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CASP9—amyotrophic lateral sclerosis	0.000124	0.000887	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.000124	0.000886	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PLB1—amyotrophic lateral sclerosis	0.000123	0.00088	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000123	0.000876	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000123	0.000876	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000121	0.000867	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	0.000121	0.000863	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.00012	0.00086	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.00012	0.000854	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.00012	0.000854	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000119	0.000852	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000118	0.000846	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000116	0.000827	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000116	0.000825	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000116	0.000825	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000114	0.000817	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000114	0.000815	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000114	0.000812	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000114	0.000812	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	0.000112	0.000803	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000112	0.000802	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000111	0.000795	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000111	0.00079	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00011	0.000788	CbGpPWpGaD
Dabrafenib—BRAF—Disease—VCP—amyotrophic lateral sclerosis	0.00011	0.000784	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000109	0.000778	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000109	0.000777	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000109	0.000777	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000107	0.000761	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000106	0.000759	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000104	0.000745	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000104	0.000742	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000103	0.000735	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	0.000101	0.000724	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000101	0.000719	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000101	0.000719	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PLB1—amyotrophic lateral sclerosis	0.0001	0.000715	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD40LG—amyotrophic lateral sclerosis	9.99e-05	0.000713	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	9.94e-05	0.00071	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—FIG4—amyotrophic lateral sclerosis	9.81e-05	0.000701	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—IGF1—amyotrophic lateral sclerosis	9.81e-05	0.000701	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	9.77e-05	0.000698	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	9.7e-05	0.000693	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.66e-05	0.00069	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	9.6e-05	0.000686	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	9.57e-05	0.000684	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—amyotrophic lateral sclerosis	9.48e-05	0.000677	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CHMP2B—amyotrophic lateral sclerosis	9.43e-05	0.000673	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	9.43e-05	0.000673	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	9.26e-05	0.000661	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSR—amyotrophic lateral sclerosis	9.24e-05	0.00066	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.2e-05	0.000657	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—FIG4—amyotrophic lateral sclerosis	9.08e-05	0.000649	CbGpPWpGaD
Dabrafenib—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	9.08e-05	0.000648	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	9.06e-05	0.000647	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	9.04e-05	0.000646	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	8.98e-05	0.000641	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—DAO—amyotrophic lateral sclerosis	8.87e-05	0.000634	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—C3—amyotrophic lateral sclerosis	8.83e-05	0.000631	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	8.69e-05	0.000621	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	8.68e-05	0.00062	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	8.63e-05	0.000616	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	8.62e-05	0.000616	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PLB1—amyotrophic lateral sclerosis	8.52e-05	0.000609	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	8.42e-05	0.000601	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	8.41e-05	0.000601	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	8.41e-05	0.000601	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	8.33e-05	0.000595	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—DAO—amyotrophic lateral sclerosis	8.22e-05	0.000587	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	8.11e-05	0.000579	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	8.1e-05	0.000578	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CST3—amyotrophic lateral sclerosis	7.88e-05	0.000563	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	7.87e-05	0.000562	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	7.78e-05	0.000556	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ATF1—amyotrophic lateral sclerosis	7.74e-05	0.000553	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	7.72e-05	0.000551	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VCP—amyotrophic lateral sclerosis	7.69e-05	0.000549	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	7.66e-05	0.000547	CbGpPWpGaD
Dabrafenib—RAF1—Disease—VCP—amyotrophic lateral sclerosis	7.6e-05	0.000543	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CHAT—amyotrophic lateral sclerosis	7.59e-05	0.000542	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—DCTN1—amyotrophic lateral sclerosis	7.53e-05	0.000537	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	7.52e-05	0.000537	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.45e-05	0.000532	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CASP9—amyotrophic lateral sclerosis	7.37e-05	0.000527	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SOD1—amyotrophic lateral sclerosis	7.35e-05	0.000525	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	7.19e-05	0.000513	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	7.1e-05	0.000507	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	7.08e-05	0.000506	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	7.05e-05	0.000504	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	7.05e-05	0.000504	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	7.04e-05	0.000503	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.92e-05	0.000494	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	6.78e-05	0.000484	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PLB1—amyotrophic lateral sclerosis	6.72e-05	0.00048	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6.61e-05	0.000472	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	6.59e-05	0.000471	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.58e-05	0.00047	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.54e-05	0.000467	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—amyotrophic lateral sclerosis	6.48e-05	0.000463	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	6.45e-05	0.000461	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	6.41e-05	0.000458	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	6.41e-05	0.000457	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	6.38e-05	0.000456	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	6.31e-05	0.000451	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	6.23e-05	0.000445	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSR—amyotrophic lateral sclerosis	6.21e-05	0.000443	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	6.14e-05	0.000439	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	6.14e-05	0.000439	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	6.1e-05	0.000435	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	6.06e-05	0.000433	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	6e-05	0.000428	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	5.97e-05	0.000426	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	5.75e-05	0.00041	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CASP9—amyotrophic lateral sclerosis	5.73e-05	0.000409	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	5.7e-05	0.000407	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	5.68e-05	0.000405	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.65e-05	0.000404	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	5.64e-05	0.000403	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	5.62e-05	0.000401	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.61e-05	0.000401	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CST3—amyotrophic lateral sclerosis	5.45e-05	0.000389	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	5.45e-05	0.000389	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	5.45e-05	0.000389	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	5.44e-05	0.000389	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	5.34e-05	0.000382	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	5.32e-05	0.00038	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—C3—amyotrophic lateral sclerosis	5.24e-05	0.000374	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.22e-05	0.000373	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	5.15e-05	0.000368	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	5.1e-05	0.000364	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CHAT—amyotrophic lateral sclerosis	5.1e-05	0.000364	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—C3—amyotrophic lateral sclerosis	5.04e-05	0.00036	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.94e-05	0.000353	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	4.91e-05	0.000351	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERBB4—amyotrophic lateral sclerosis	4.9e-05	0.00035	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.87e-05	0.000348	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	4.86e-05	0.000347	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	4.82e-05	0.000344	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SQSTM1—amyotrophic lateral sclerosis	4.81e-05	0.000343	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.74e-05	0.000339	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	4.72e-05	0.000337	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP9—amyotrophic lateral sclerosis	4.66e-05	0.000332	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.65e-05	0.000332	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	4.61e-05	0.000329	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.57e-05	0.000327	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.52e-05	0.000323	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ATF1—amyotrophic lateral sclerosis	4.51e-05	0.000322	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.49e-05	0.000321	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IGF1—amyotrophic lateral sclerosis	4.48e-05	0.00032	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	4.44e-05	0.000317	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CASP9—amyotrophic lateral sclerosis	4.29e-05	0.000307	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.21e-05	0.000301	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	4.18e-05	0.000299	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.08e-05	0.000291	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.01e-05	0.000287	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CASP9—amyotrophic lateral sclerosis	3.96e-05	0.000283	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	3.86e-05	0.000276	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	3.82e-05	0.000273	CbGpPWpGaD
Dabrafenib—BRAF—Disease—APOE—amyotrophic lateral sclerosis	3.79e-05	0.000271	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	3.79e-05	0.00027	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	3.79e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.78e-05	0.00027	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.75e-05	0.000268	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB4—amyotrophic lateral sclerosis	3.68e-05	0.000262	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	3.57e-05	0.000255	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.55e-05	0.000253	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	3.46e-05	0.000247	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40LG—amyotrophic lateral sclerosis	3.46e-05	0.000247	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.43e-05	0.000245	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB4—amyotrophic lateral sclerosis	3.39e-05	0.000242	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.37e-05	0.00024	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.34e-05	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	3.32e-05	0.000237	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.25e-05	0.000232	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.23e-05	0.000231	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.22e-05	0.00023	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.19e-05	0.000228	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.11e-05	0.000222	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	3.11e-05	0.000222	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—APOE—amyotrophic lateral sclerosis	3.08e-05	0.00022	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—C3—amyotrophic lateral sclerosis	3.05e-05	0.000218	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	3.03e-05	0.000216	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.01e-05	0.000215	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.98e-05	0.000213	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	2.93e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.93e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.92e-05	0.000208	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.85e-05	0.000204	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.78e-05	0.000198	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.74e-05	0.000196	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	2.74e-05	0.000195	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.67e-05	0.000191	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.66e-05	0.00019	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOE—amyotrophic lateral sclerosis	2.63e-05	0.000187	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—amyotrophic lateral sclerosis	2.6e-05	0.000186	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.55e-05	0.000182	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.54e-05	0.000181	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.52e-05	0.00018	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.38e-05	0.00017	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.33e-05	0.000166	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.27e-05	0.000162	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.23e-05	0.00016	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—amyotrophic lateral sclerosis	2.21e-05	0.000158	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.2e-05	0.000157	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.11e-05	0.000151	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	2.07e-05	0.000148	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—amyotrophic lateral sclerosis	2.07e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.97e-05	0.000141	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	1.92e-05	0.000137	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.91e-05	0.000137	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.84e-05	0.000131	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.83e-05	0.000131	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—amyotrophic lateral sclerosis	1.8e-05	0.000128	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.69e-05	0.000121	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.6e-05	0.000114	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.57e-05	0.000112	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.57e-05	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.52e-05	0.000108	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.45e-05	0.000103	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.43e-05	0.000102	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.42e-05	0.000101	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.37e-05	9.79e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.31e-05	9.38e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.26e-05	9e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	1.19e-05	8.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.17e-05	8.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.1e-05	7.89e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.08e-05	7.74e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.04e-05	7.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.92e-06	7.09e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.45e-06	6.03e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.15e-06	5.82e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.76e-06	5.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.5e-06	5.35e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.1e-06	5.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	6.39e-06	4.56e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.38e-06	3.13e-05	CbGpPWpGaD
